Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase: 1b/2a
Status: Ongoing
About
Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid
Tumors.
Details
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy
of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination
With Pembrolizumab in Patients With Advanced Solid Tumors.
Sponsor: TiumBio Co, Ltd
NCT05784688